Sulforaphane enhances TRAIL-induced apoptosis through the induction of DR5 expression in human osteosarcoma cells

Carcinogenesis

Volumn 27, Issue 9, 2006, Pages 1768-1777

  Matsui, Taka Aki ^a   Sowa, Yoshihiro ^a   Yoshida, Tatsushi ^a   Murata, Hiroaki ^a   Horinaka, Mano ^a   Wakada, Miki ^a   Nakanishi, Ryoko ^a   Sakabe, Tomoya ^a   Kubo, Toshikazu ^a   Sakai, Toshiyuki ^a  

^a KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 10; CASPASE 3; CASPASE 8; CASPASE 9; CASPASE INHIBITOR; DEATH RECEPTOR 5; MESSENGER RNA; PROTEIN BID; PROTEIN P53; SMALL INTERFERING RNA; SULFORAPHANE; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENCY; DRUG POTENTIATION; DRUG TARGETING; ENZYME ACTIVATION; HUMAN; HUMAN CELL; OSTEOSARCOMA; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; UPREGULATION;

ANTICARCINOGENIC AGENTS; ANTINEOPLASTIC AGENTS; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; CASPASES; CELL LINE; CELL LINE, TUMOR; ENZYME ACTIVATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LEUKOCYTES, MONONUCLEAR; MEMBRANE GLYCOPROTEINS; OSTEOSARCOMA; RECEPTORS, TNF-RELATED APOPTOSIS-INDUCING LIGAND; RECEPTORS, TUMOR NECROSIS FACTOR; THIOCYANATES; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TUMOR NECROSIS FACTOR-ALPHA;

EID: 33747892514     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgl015     Document Type: Article

References (39)

1. Meyers,P.A., Heller,G., Healey,J., Huvos,A., Lane,J., Marcove,R., Applewhite,A., Vlamis,V. and Rosen,G. (1992) Chemotherapy for nonmetastatic osteogenic sarcoma: The Memorial Sloan-Kettering experience. J. Clin. Oncol., 10, 5-15.
2. Bramwell,V.H, Burgers,M., Sneath,R. et al. (1992) A comparision of two short intensive adjuvant chemotherapy regimens in operable osteosarcima of limbs in children and young adults: The first study of the European Osteosarcoma Intergroup. J. Clin. Oncol., 10, 1579-1591.
3. Patel,S.J., Lynch,J.W. Jr, Jhonson,T., Carroll,R.R., Schumacher,C., Spanier,S. and Scarborough,M. (2002) Dose-intense ifosfamide/doxorubicin/ cisplatin based chemotherapy for osteosarcoma in adults. Am. J. Clin. Oncol., 25, 489-495.
4. Zalupski,M.M., Rankin,C., Ryan,J.R., Lucas,D.R., Muler,J., Lanier,K.S., Budd,G.T., Biermann,J.S., Meyers,F.J. and Antman,K. (2004) Adjuvant therapy of osteosarcoma- A phase α trial: Southwest Oncology Group study 9139. Cancer, 100, 818-825.
5. Marina,N.M., Pratt,C.B., Rao,B.N., Shema,S.J. and Meyer,W.H. (1992) Improved prognosis of children with osteosarcoma metastatic to the lung(s) at the time of diagnosis. Cancer, 70, 2722-2727.
6. Voute,P.A., Souhami,R.L., Nooij,M. et al. (1999) A phase α study of cisplatin, ifosfamide and doxorubicin in operable primary, axial skeletal and metastatic osteosarcoma. European Osteosarcoma Intergroup (EOI). Ann. Oncol., 10, 1211-1218.
7. Ozaki,T., Flege,S., Kevric,M. et al. (2003) Osteosarcoma of the pelvis: experience of the Cooperative Osteosarcoma Study Group. J. Clin. Oncol., 21, 334-341.
8. Bacci,G., Briccoli,A., Rocca,M. et al. (2003) Neoadjuvant chemotherapy for osteosarcoma of the extremities with metastases at presentation: recent experience at the Rizzoli Institute in 57 patients treated with cisplatin, doxorubicin, and a high dose of methotrexate and ifosfamide. Ann. Oncol., 14, 1126-1134.
9. Patel,S.R., Papadopolous,N., Raymond,A.K., Donato,M., Seong,C.M., Yasko,A.W., Lewis,V.O., Lin,P.P., Champlin,R. and Benjamin,R.S. (2004) A phase α study of cisplatin, doxorubicin and ifosfamide with peripheral blood stem cell support in patients with skeletal osteosarcoma and variant bone tumors with a poor prognosis. Cancer, 101, 156-163.
10. Walczak,H., Miller,R.E., Ariail,K. et al. (1999) Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat. Med., 5, 157-163.
11. Ashkenazi,A., Pai,R.C., Fong,S. et al. (1999) Safety and antitumor activity of recombinant soluble Apo2 ligand. J. Clin. Invest., 104, 155-162.
12. Pan,G., Ni,J., Wei,Y.F., Yu,G., Gentz,R. and Dixit,V.M. (1997) An antagonist decoy receptor and a death domain-containing receptor for TRAIL. Science, 277, 815-818.
13. Sheridan,J.P., Marsters,S.A., Pitti,R.M. et al. (1997) Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors. Science, 277, 818-821.
14. Wu,G.S., Burns,T.F., McDonald,E.R. III et al. (1997) KILLER/DR5 is a DNA damage-inducible p53-regulated death receptor gene. Nat. Genet., 17, 141-143.
15. LeBlanc,H.N. and Ashkenazi,A. (2003) Apo2L/TRAIL and its death and decoy receptors. Cell Death Differ., 10, 66-75.
16. Wu,G.S., Burns,T.F., McDonald,E.R. III, Meng,R.D., Kao,G., Muschel,R., Yen,T. and El-Deiry,W.S. (1999) Induction of the TRAIL receptor KILLER/ DR5 in p53-dependent apoptosis but not growth arrest. Oncogene, 18, 6411-6418.
17. Takimoto,R. and El-Deiry,W.S. (2000) Wild-type p53 transactivates the KILLER/DR5 gene through an intronic sequence-specific DNA-binding site. Oncogene, 19, 1735-1743.
18. Wang,S. and El-Deiry,W.S. (2004) Inducible silencing of KILLER/DR5 in vivo promotes bioluminescent colon tumor xenograft growth and confers resistance to chemotherapeutic agent 5-fluorouracil. Cancer Res, 64, 6666-6672.
19. Zhang,Y., Talalay,P., Cho,C.G. and Posner,G.H. (1992) A major inducer of anticarcinogenic protective enzymes from broccoli: Isolation and elucidation of structure. Proc. Natl Acad. Sci. USA, 89, 2399-2403.
20. Zhang,Y., Kensler,T.W., Cho,C.G., Posner,G.H. and Talalay,P. (1994) Anticarcinogenic activities of sulforaphane and structurally related syn-thetic norbornyl isothiocyanates. Proc. Natl Acad. Sci. USA, 91, 3147-3150.
21. Fahey,J.W., Zhang,Y. and Talalay,P. (1997) Broccoli sprouts: An exceptionally rich source of inducers of enzymes that protect against chemical carcinogens. Proc. Natl Acad. Sci. USA., 94, 10367-10372.
22. Chung,F.L., Conaway,C.C., Rao,C.V. and Reddy,B.S. (2000) Chemoprevention of colonic aberrant crypt foci in Fischer rats by sulforaphane and phenetyl isothiocyanate. Carcinogenesis, 21, 2287-2291.
23. Fahey,J.W., Haristoy,X., Dolan,P.M., Kensler,T.W., Scholtus,I., Stephenson,K.K., Talalay,P. and Lozniewski,A. (2002) Sulforaphane inhibits extracellular, intacellular, and antibiotic-resistant strains of Helicobacter pylori and prevents benzo(a)pyrene-induced stomach tumors. Proc. Natl Acad. Sci. USA, 99, 7610-7615.
24. Singh,A.V., Xiao,D., Lew,K.L., Dhir,R. and Singh,S.V. (2004) Sulforaphane induces caspase-mediated apoptosis in cultured PC-3 human prostate cancer cells and retards growth of PC-3 xenografts in vivo. Carcinogenesis, 25, 83-90.
25. Jackson,S.J. and Singletary,K.W. (2004) Sulforaphane: A naturally occurring mammary carcinoma mitotic inhibitor, which disrupts tubulin polymerization. Carcinogenesis, 25, 219-227.
26. Gamet-Payrastre,L., Li,P., Lumeau,S., Cassar,G., Dupont,M.A., Chevolleau,S., Gasc,N., Tulliez,J. and Terce,F. (2000) Sulforaphane, a naturally occurring isothiocyanate, induces cell cycle arrest and apoptosis in HT29 human colon cancer cells. Cancer Res, 60, 1426-1433.
27. Fimognari,C., Nusse,M., Cesari,R., Iori,R., Cantelli-Forti,G. and Hrelia,P. (2002) Growth inhibition, cell-cycle arrest and apoptosis in human T-cell leukemia by the isothiocyanate sulforaphane. Carcinogenesis, 23, 581-586.
28. Parnaud,G., Li,.P, Cassar,G., Rouimi,P., Tulliez,J., Combaret,L. and Gamet-Payrastre,L. (2004) Mechanism of sulforaphane-induced cell cycle arrest and apoptosis in human colon cancer cells. Nutr. Cancer, 48, 198-206.
29. 2-M phase cell cycle arrest involves checkpoint kinase 2-mediated phosphorylation of cell division cycle 25C. J. Biol. Chem., 279, 25813-25822.
30. Choi,S. and Singh,S.V. (2005) Bax and Bak are required for apoptosis induction by sulforaphane, a cruciferous vegetable-derived cancer chemopreventive agent. Cancer Res, 65, 2035-2043.
31. Nakata,S., Yoshida,T., Horinaka,M., Shiraishi,T., Wakada,M. and Sakai,T. (2004) Histone deacetylase inhibitors upregulate death receptor 5/ TRAIL-R2 and sensitize apoptosis induced by TRAIL/APO2-L in human malignant tumor cells. Oncogene, 23, 6261-6271.
32. Horinaka,M., Yoshida,T., Shiraishi,T., Nakata,S., Wakada,M., Nakanishi,R., Nishino,H., Matsui,H. and Sakai,T. (2005) Luteolin induces apoptosis via death receptor 5 upregulation in human malignant tumor cells. Oncogene, 24, 7180-7189.
33. Yamaguchi,.H and Wang,H.G. (2004) CHOP is involved in endoplasmic reticulum stress-induced apoptosis by enhancing DR5 expression in human carcinoma cells. J. Biol. Chem., 279, 45495-45502.
34. Toguchida,J., Yamaguchi,T., Ritchie,B. et al. (1992) Mutation spectrum of the p53gene in bone and soft tissue sarcomas. Cancer Res., 52, 6194-6199.
35. Lowe,S.W., Ruley,H.E., Jacks,T. and Housman,D.E. (1993) p53 dependent apoptosis modulates the cytotoxicity of anticancer drugs. Cell, 74, 957-967.
36. Wang,L.H., Okaichi,K., Ihara,M. and Okumura,Y. (1998) Sensitivity of anticancer drugs in Saos-2 cells transfected with mutant p53 varied with mutation point. Anticancer Res., 18, 321-325.
37. Ye,L., Dinkova-Kostova,A.T., Wade,K.L., Zhang,Y., Shapiro,T.A. and Talalay,P. (2002) Quantitative determination of dithiocarbamates in human plasma, serum, erythrocytes and urine: Pharmacokinetics of broccoli sprout isothiocyanates in humans. Clin. Chim. Acta., 316, 43-53.
38. Hu,R., Hebbar,V., Kim,B.R., Chen,C., Winnik,B., Buckley,B., Soteropoulos,P., Tolias,P., Hart,R.P. and Kong,A.N. (2004) In vivopharmacokinetics and regulation of gene expression profiles by isothiocyanate sulforaphane in the rat. J. Pharmacol. Exp. Ther., 310, 263-271.
39. Myzak,M.C., Karplus,P.A., Chung,F.L. and Dashwood,R.H. (2004) A novel mechanism of chemoprotection by sulforaphane: Inhibition of histone deacetylase. Cancer Res., 64, 5767-5774.